NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

BIVI

BioVie Inc

May 08 • 04:00PM ET

1.23

Dollar change +0.15
Percentage change 13.89	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY NBIX SAVA PRTA EQ ANVS ACAD AUTL AXSM

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.95	Insider Own	13.06%	Shs Outstand	18.45M	Perf Week	42.69%
Market Cap	22.70M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	0.00%	Shs Float	16.04M	Perf Month	73.73%
Income	-25.53M	PEG	-	EPS next Q	-0.32	Inst Own	3.62%	Short Float	7.09%	Perf Quarter	-37.56%
Sales	0.00M	P/S	-	EPS this Y	81.64%	Inst Trans	170.99%	Short Ratio	2.59	Perf Half Y	-51.00%
Book/sh	1.30	P/B	0.95	EPS next Y	-21.64%	ROA	-102.89%	Short Interest	1.14M	Perf Year	-74.71%
Cash/sh	1.32	P/C	0.93	EPS next 5Y	-	ROE	-154.54%	52W Range	0.62 - 7.50	Perf YTD	-38.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.73%	ROI	-105.33%	52W High	-83.60%	Beta	1.16
Dividend TTM	-	Quick Ratio	16.94	Sales past 5Y	0.00%	Gross Margin	-	52W Low	98.39%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	16.94	EPS Y/Y TTM	66.72%	Oper. Margin	-	RSI (14)	63.08	Volatility	25.13% 14.79%
Employees	14	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	79.31%	Payout	-	Rel Volume	1.77	Prev Close	1.08
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	438.98K	Price	1.23
SMA20	35.12%	SMA50	23.69%	SMA200	-40.68%	Trades		Volume	776,543	Change	13.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-22	Initiated	Cantor Fitzgerald	Overweight	$7
Jan-15-21	Initiated	B. Riley Securities	Buy	$47

May-07-25 08:00AM	BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025) (GlobeNewswire) -6.90%
May-05-25 08:00AM	BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth (GlobeNewswire) -5.79%
Apr-16-25 08:00AM	BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled (GlobeNewswire)
Mar-27-25 08:00AM	BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025 (GlobeNewswire)
Mar-10-25 10:35AM	New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI) (ACCESS Newswire) -8.40%
08:40PM	Loading…
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire) -11.28%
Feb-22-25 12:15PM	New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tanks Kevin Harrington and Sustainable Green Team (SGTM) (ACCESS Newswire)
Jan-13-25 09:00AM	BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events (ACCESS Newswire)
Nov-20-24 08:00AM	BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference (GlobeNewswire)
Nov-04-24 08:00AM	BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded (GlobeNewswire) -9.39%
Oct-29-24 04:05PM	BioVie Inc. Announces Closing of Registered Direct Offering (GlobeNewswire) -10.80% +10.94%
Oct-28-24 04:10PM	UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
03:13PM	BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-24 04:10PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +5.45% +5.54%
Oct-23-24 03:24PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.51%
09:19AM	Loading…
09:19AM	BioVie Announces Stock Offering and Private Placement (TipRanks)
08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 (GlobeNewswire)
Oct-22-24 04:01PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +27.76%
Oct-21-24 03:08PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +11.91%
Oct-15-24 08:00AM	BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Oct-11-24 09:00AM	BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-01-24 08:00AM	BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Sep-25-24 04:05PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire) -7.50%
Sep-23-24 10:26PM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire) -57.86%
04:05PM	BioVie Inc. Announces Proposed Public Offering (GlobeNewswire)
Sep-16-24 08:00AM	BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Sep-03-24 08:00AM	BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Aug-27-24 08:45AM	BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-13-24 08:00AM	BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -10.08%
06:00AM	Loading…
Aug-08-24 06:00AM	BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease (GlobeNewswire) +13.30%
Aug-06-24 04:40PM	BioVie Inc. Announces Reverse Stock Split (GlobeNewswire) -21.40% -5.63%
Jul-05-24 09:00AM	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-25-24 08:00AM	BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024 (GlobeNewswire) -5.32%
Jun-21-24 09:00AM	BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-20-24 08:00AM	BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress (GlobeNewswire)
Jun-12-24 08:24AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26 (GlobeNewswire)
Jun-04-24 08:00AM	BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID (GlobeNewswire)
May-22-24 08:00AM	BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients (GlobeNewswire)
May-15-24 10:53AM	BIVI Stock Earnings: BioVie Beats EPS for Q3 2024 (InvestorPlace)
Apr-29-24 11:43AM	BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID (MT Newswires)
08:00AM	BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID (GlobeNewswire)
Apr-25-24 08:00AM	BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints (GlobeNewswire)
Apr-18-24 08:00AM	BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation (GlobeNewswire)
Apr-12-24 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Mar-26-24 10:30AM	Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation (PR Newswire) -6.17%
Mar-13-24 11:30AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie (PR Newswire) +6.93%
Mar-12-24 09:55AM	Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now (Zacks)
09:41AM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Mar-11-24 10:48AM	BioVie cuts 'most de-risked program,' will seek partners for phase-3 ready ascites program (FierceBiotech.com)
08:00AM	BioVie Announces Pipeline Update and Near-Term Clinical Priorities (GlobeNewswire)
Mar-06-24 06:21PM	BIVI INVESTORS: Lead Plaintiff is Quickly Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire) -8.02% -10.25%
05:00PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire)
Mar-05-24 11:39AM	Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights BIVI (GlobeNewswire) -15.24%
Mar-04-24 05:16PM	BioVie Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline. (GlobeNewswire) -43.65%
08:51AM	Why Is BioVie (BIVI) Stock Down 41% Today? (InvestorPlace)
01:32AM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire)
Mar-01-24 04:58PM	BioVie Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +52.42%
04:58PM	BioVie Inc. Announces Proposed Public Offering of Common Stoc (GlobeNewswire)
10:57AM	Why Is BioVie (BIVI) Stock Up 100% Today? (InvestorPlace)
08:00AM	BioVie's NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for Alzheimer's Patients in Data to be Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2024 (GlobeNewswire)
Feb-23-24 04:49PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire) -5.60%
12:30PM	BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options (GlobeNewswire)
05:45AM	BioVie Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIVI (PR Newswire)
Feb-19-24 01:12PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire)
Feb-09-24 03:40PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire) +6.36%
Feb-07-24 01:00PM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Feb-06-24 08:00AM	BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.83%
Jan-29-24 01:28PM	Investors Sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Hagens Berman (GlobeNewswire) +12.07%
Jan-27-24 05:29AM	18 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-25-24 12:34PM	Investors sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Hagens Berman (GlobeNewswire)
Jan-24-24 11:30AM	BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-19-24 07:18PM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Jan-17-24 03:14PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioVie (BIVI) Investors with Substantial Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations (GlobeNewswire)
Jan-11-24 10:25AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Jan-05-24 02:08PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
09:00AM	bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-29-23 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-25-23 11:15AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-22-23 09:00AM	Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-21-23 10:25AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-18-23 02:32PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-13-23 04:36PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire) -6.49%
Dec-11-23 09:35AM	BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-04-23 03:23PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Nov-30-23 02:21PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire) -8.16%
10:20AM	BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data (Zacks)
Nov-29-23 11:38AM	Why Is BioVie (BIVI) Stock Down 63% Today? (InvestorPlace) -60.72%
09:34AM	BioVie blames protocol errors at trial sites for phase 3 Alzheimer's drug fail as stock craters (FierceBiotech.com)
08:00AM	BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer's Disease (GlobeNewswire)
Nov-13-23 08:00AM	BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2023 (GlobeNewswire)
Nov-10-23 09:00AM	DevvStream Holdings Inc. and BioVie Inc. Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE) +8.97%
Nov-02-23 08:00AM	BioVie to Participate in the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-30-23 01:00PM	BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial (News Direct) +21.32%
08:00AM	BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET (GlobeNewswire)
Oct-26-23 08:00AM	BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD The Liver Meeting 2023 (GlobeNewswire)
Oct-25-23 12:30PM	Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer's Disease Patients (GlobeNewswire) -5.97%
Oct-19-23 10:00AM	Best Momentum Stocks to Buy for October 19th (Zacks) +7.10%
07:30AM	BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer's Disease at CTAD (GlobeNewswire)
Sep-26-23 08:00AM	BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease (GlobeNewswire) +8.62%

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIVI

BioVie Inc

Upgrade your FINVIZ experience